1. Home
  2. BKYI vs SNOA Comparison

BKYI vs SNOA Comparison

Compare BKYI & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BKYI

BIO-key International Inc.

HOLD

Current Price

$0.57

Market Cap

6.8M

Sector

Technology

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$2.13

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKYI
SNOA
Founded
1993
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8M
6.1M
IPO Year
2013
2006

Fundamental Metrics

Financial Performance
Metric
BKYI
SNOA
Price
$0.57
$2.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
190.8K
17.9K
Earning Date
05-14-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,302,984.00
$14,288,000.00
Revenue This Year
$7.45
$23.00
Revenue Next Year
$23.29
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
111.81
12.19
52 Week Low
$0.51
$1.77
52 Week High
$1.97
$6.92

Technical Indicators

Market Signals
Indicator
BKYI
SNOA
Relative Strength Index (RSI) 42.23 31.14
Support Level $0.53 N/A
Resistance Level $0.63 $3.85
Average True Range (ATR) 0.05 0.15
MACD -0.01 -0.02
Stochastic Oscillator 6.75 8.93

Price Performance

Historical Comparison
BKYI
SNOA

About BKYI BIO-key International Inc.

BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: